

# World Journal of *Clinical Cases*

*World J Clin Cases* 2021 July 6; 9(19): 4881-5351



**OPINION REVIEW**

- 4881 Fear of missing out: A brief overview of origin, theoretical underpinnings and relationship with mental health  
*Gupta M, Sharma A*

**REVIEW**

- 4890 Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update  
*Elpek GO*
- 4918 Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions  
*Oikonomou KG, Papamichalis P, Zafeiridis T, Xanthoudaki M, Papapostolou E, Valsamaki A, Bouliaris K, Papamichalis M, Karvouniaris M, Vlachostergios PJ, Skoura AL, Komnos A*
- 4939 Enhancing oxygenation of patients with coronavirus disease 2019: Effects on immunity and other health-related conditions  
*Mohamed A, Alawna M*

**MINIREVIEWS**

- 4959 Clinical potentials of ginseng polysaccharide for treating gestational diabetes mellitus  
*Zhao XY, Zhang F, Pan W, Yang YF, Jiang XY*
- 4969 Remarkable gastrointestinal and liver manifestations of COVID-19: A clinical and radiologic overview  
*Fang LG, Zhou Q*
- 4980 Liver injury in COVID-19: Known and unknown  
*Zhou F, Xia J, Yuan HX, Sun Y, Zhang Y*
- 4990 COVID-19 and gastroenteric manifestations  
*Chen ZR, Liu J, Liao ZG, Zhou J, Peng HW, Gong F, Hu JF, Zhou Y*
- 4998 Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma  
*Hu X, Chen W*
- 5007 Insights into the virologic and immunologic features of SARS-COV-2  
*Polat C, Ergunay K*

**ORIGINAL ARTICLE****Basic Study**

- 5019** SMAC exhibits anti-tumor effects in ECA109 cells by regulating expression of inhibitor of apoptosis protein family

*Jiang N, Zhang WQ, Dong H, Hao YT, Zhang LM, Shan L, Yang XD, Peng CL*

**Case Control Study**

- 5028** Efficacy of Solitaire AB stent-release angioplasty in acute middle cerebral artery atherosclerosis obliterative cerebral infarction

*Wang XF, Wang M, Li G, Xu XY, Shen W, Liu J, Xiao SS, Zhou JH*

**Retrospective Study**

- 5037** Diagnostic value of different color ultrasound diagnostic method in endometrial lesions

*Lin XL, Zhang DS, Ju ZY, Li XM, Zhang YZ*

- 5046** Clinical and pathological features and risk factors for primary breast cancer patients

*Lei YY, Bai S, Chen QQ, Luo XJ, Li DM*

- 5054** Outcomes of high-grade aneurysmal subarachnoid hemorrhage patients treated with coiling and ventricular intracranial pressure monitoring

*Wen LL, Zhou XM, Lv SY, Shao J, Wang HD, Zhang X*

- 5064** Microwave ablation combined with hepatectomy for treatment of neuroendocrine tumor liver metastases

*Zhang JZ, Li S, Zhu WH, Zhang DF*

- 5073** Clinical application of individualized total arterial coronary artery bypass grafting in coronary artery surgery

*Chen WG, Wang BC, Jiang YR, Wang YY, Lou Y*

**Observational Study**

- 5082** Early diagnosis, treatment, and outcomes of five patients with acute thallium poisoning

*Wang TT, Wen B, Yu XN, Ji ZG, Sun YY, Li Y, Zhu SL, Cao YL, Wang M, Jian XD, Wang T*

- 5092** Sarcopenia in geriatric patients from the plateau region of Qinghai-Tibet: A cross-sectional study

*Pan SQ, Li YM, Li XF, Xiong R*

- 5102** Medium-term efficacy of arthroscopic debridement *vs* conservative treatment for knee osteoarthritis of Kellgren-Lawrence grades I-III

*Lv B, Huang K, Chen J, Wu ZY, Wang H*

**Prospective Study**

- 5112** Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea

*Hirono H, Watanabe K, Hasegawa K, Kohno M, Terai S, Ohkoshi S*

**Randomized Controlled Trial**

- 5126 Erector spinae plane block at lower thoracic level for analgesia in lumbar spine surgery: A randomized controlled trial  
*Zhang JJ, Zhang TJ, Qu ZY, Qiu Y, Hua Z*

**SYSTEMATIC REVIEWS**

- 5135 Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages  
*Liatsos GD*
- 5179 Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis  
*Zhang JB, Chen J, Zhou J, Wang XM, Chen S, Chu JG, Liu P, Ye ZD*

**CASE REPORT**

- 5191 Myelodysplastic syndrome transformed into B-lineage acute lymphoblastic leukemia: A case report  
*Zhu YJ, Ma XY, Hao YL, Guan Y*
- 5197 Imaging presentation and postoperative recurrence of peliosis hepatis: A case report  
*Ren SX, Li PP, Shi HP, Chen JH, Deng ZP, Zhang XE*
- 5203 Delayed retroperitoneal hemorrhage during extracorporeal membrane oxygenation in COVID-19 patients: A case report and literature review  
*Zhang JC, Li T*
- 5211 Autologous tenon capsule packing to treat posterior exit wound of penetrating injury: A case report  
*Yi QY, Wang SS, Gui Q, Chen LS, Li WD*
- 5217 Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: A case report and review of the literature  
*Yang JW, Hua Y, Xu H, He L, Huo HZ, Zhu CF*
- 5226 Homozygous deletion, c. 1114-1116del, in exon 8 of the *CRPPA* gene causes congenital muscular dystrophy in Chinese family: A case report  
*Yang M, Xing RX*
- 5232 Successful diagnosis and treatment of jejunal diverticular haemorrhage by full-thickness enterotomy: A case report  
*Ma HC, Xiao H, Qu H, Wang ZJ*
- 5238 Liver metastasis as the initial clinical manifestation of sublingual gland adenoid cystic carcinoma: A case report  
*Li XH, Zhang YT, Feng H*
- 5245 Severe hyperbilirubinemia in a neonate with hereditary spherocytosis due to a *de novo* ankyrin mutation: A case report  
*Wang JF, Ma L, Gong XH, Cai C, Sun JJ*

- 5252** Long-term outcome of indwelling colon observed seven years after radical resection for rectosigmoid cancer: A case report  
*Zhuang ZX, Wei MT, Yang XY, Zhang Y, Zhuang W, Wang ZQ*
- 5259** Diffuse xanthoma in early esophageal cancer: A case report  
*Yang XY, Fu KI, Chen YP, Chen ZW, Ding J*
- 5266** COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report  
*Wu YF, Yu WJ, Jiang YH, Chen Y, Zhang B, Zhen RB, Zhang JT, Wang YP, Li Q, Xu F, Shi YJ, Li XP*
- 5270** Maintenance treatment with infliximab for ulcerative ileitis after intestinal transplantation: A case report  
*Fujimura T, Yamada Y, Umeyama T, Kudo Y, Kanamori H, Mori T, Shimizu T, Kato M, Kawaida M, Hosoe N, Hasegawa Y, Matsubara K, Shimojima N, Shinoda M, Obara H, Naganuma M, Kitagawa Y, Hoshino K, Kuroda T*
- 5280** Infliximab treatment of glycogenosis Ib with Crohn's-like enterocolitis: A case report  
*Gong YZ, Zhong XM, Zou JZ*
- 5287** Hemichorea due to ipsilateral thalamic infarction: A case report  
*Li ZS, Fang JJ, Xiang XH, Zhao GH*
- 5294** Intestinal gangrene secondary to congenital transmesenteric hernia in a child misdiagnosed with gastrointestinal bleeding: A case report  
*Zheng XX, Wang KP, Xiang CM, Jin C, Zhu PF, Jiang T, Li SH, Lin YZ*
- 5302** Collagen VI-related myopathy with scoliosis alone: A case report and literature review  
*Li JY, Liu SZ, Zheng DF, Zhang YS, Yu M*
- 5313** Neuromuscular electrical stimulation for a dysphagic stroke patient with cardiac pacemaker using magnet mode change: A case report  
*Kim M, Park JK, Lee JY, Kim MJ*
- 5319** Four-year-old anti-N-methyl-D-aspartate receptor encephalitis patient with ovarian teratoma: A case report  
*Xue CY, Dong H, Yang HX, Jiang YW, Yin L*
- 5325** Glutamic acid decarboxylase 65-positive autoimmune encephalitis presenting with gelastic seizure, responsive to steroid: A case report  
*Yang CY, Tsai ST*
- 5332** Ectopic opening of the common bile duct into the duodenal bulb with recurrent choledocholithiasis: A case report  
*Xu H, Li X, Zhu KX, Zhou WC*
- 5339** Small bowel obstruction caused by secondary jejunal tumor from renal cell carcinoma: A case report  
*Bai GC, Mi Y, Song Y, Hao JR, He ZS, Jin J*
- 5345** Brugada syndrome associated with out-of-hospital cardiac arrest: A case report  
*Ni GH, Jiang H, Men L, Wei YY, A D, Ma X*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Fan-Bo Meng, MD, PhD, Chief Doctor, Deputy Director, Professor, Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130000, Jilin Province, China. mengfb@jlu.edu.cn

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

*WJCC* mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The *WJCC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJCC* as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3. The *WJCC*'s CiteScore for 2019 is 0.3 and Scopus CiteScore rank 2019: General Medicine is 394/529.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yan-Xia Xing, Production Department Director: Yun-Xiaoqian Wu, Editorial Office Director: Jin-Lai Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Dennis A Bloomfield, Sandro Vento, Bao-Gan Peng

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

July 6, 2021

**COPYRIGHT**

© 2021 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report

Yi-Feng Wu, Wan-Jun Yu, Yu-Hua Jiang, Yin Chen, Bo Zhang, Rui-Bing Zhen, Jun-Tao Zhang, Yi-Ping Wang, Qiang Li, Feng Xu, Yan-Jun Shi, Xian-Peng Li

**ORCID number:** Yi-Feng Wu 0000-0001-9437-3307; Wan-Jun Yu 0000-0001-9437-3308; Yu-Hua Jiang 0000-0001-9437-4022; Yin Chen 0000-0001-9431-5901; Bo Zhang 0000-0001-9433-7891; Rui-Bing Zhen 0000-0001-9433-7856; Jun-Tao Zhang 0000-0001-9434-5812; Yi-Ping Wang 0000-0001-9433-7681; Qiang Li 0000-0001-9434-7821; Feng Xu 0000-0002-4467-2787; Yan-Jun Shi 0000-0001-9434-6754; Xian-Peng Li 0000-0001-9437-3334.

**Author contributions:** Wu YF, Yu WJ, Jiang YH, Chen Y, Zhang B, Zhen RB, Zhang JT, Wang YP, Li Q, Xu F, and Shi YJ cared for the patient; Wu YF and Li XP reviewed the literature and were primarily responsible for writing the manuscript; Li XP critically reviewed and edited the manuscript.

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist, and the manuscript was prepared and revised according to

**Yi-Feng Wu**, Department of Hepatobiliary and Pancreas Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Wan-Jun Yu, Rui-Bing Zhen**, Department of Respiratory Disease and Critical Care Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Yu-Hua Jiang, Yin Chen, Bo Zhang, Xian-Peng Li**, Department of Infectious Diseases, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Jun-Tao Zhang**, Department of Ophthalmology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Yi-Ping Wang**, Department of Laboratory Medicine, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Qiang Li**, Department of Radiology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Feng Xu**, Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China

**Yan-Jun Shi**, Department of Hepatobiliary and Pancreas Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 315009, Zhejiang Province, China

**Corresponding author:** Xian-Peng Li, MD, PhD, Chief Doctor, Department of Infectious Diseases, The Affiliated People's Hospital of Ningbo University, No. 251 Baizhang Road, Ningbo 315040, Zhejiang Province, China. [rmlixianpeng@nbu.edu.cn](mailto:rmlixianpeng@nbu.edu.cn)

### Abstract

#### BACKGROUND

Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported.

#### CASE SUMMARY

A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d.

the CARE Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Infectious Diseases

**Country/Territory of origin:** China

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C, C  
Grade D (Fair): D, D  
Grade E (Poor): 0

**Received:** February 3, 2021

**Peer-review started:** February 3, 2021

**First decision:** February 28, 2021

**Revised:** March 3, 2021

**Accepted:** May 15, 2021

**Article in press:** May 15, 2021

**Published online:** July 6, 2021

**P-Reviewer:** Hammad M, Lashen SA, Pavidis M

**S-Editor:** Wang JL

**L-Editor:** Wang TQ

**P-Editor:** Xing YX



## CONCLUSION

COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.

**Key Words:** COVID-19; Hepatitis B virus; Reactivation; Diagnose; Therapy; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In this study, the authors found that coronavirus disease 2019 or treatment associated immunosuppression may trigger hepatitis B virus reactivation.

**Citation:** Wu YF, Yu WJ, Jiang YH, Chen Y, Zhang B, Zhen RB, Zhang JT, Wang YP, Li Q, Xu F, Shi YJ, Li XP. COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report. *World J Clin Cases* 2021; 9(19): 5266-5269

**URL:** <https://www.wjgnet.com/2307-8960/full/v9/i19/5266.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v9.i19.5266>

## INTRODUCTION

Hepatitis B virus (HBV) reactivation occurs primarily when body immunity declines due to the use of chemotherapy, long-term glucocorticoids, or immunosuppressive therapy[1]. Coronavirus disease 2019 (COVID-19) is an emerging global viral infectious disease. The pathogenesis of COVID-19 is still unclear[2]. Whether HBV reactivation occurs in COVID-19 patients has not yet been reported.

## CASE PRESENTATION

### Chief complaints

A 45-year-old man was admitted to the hospital for fever and fatigue after his way back from Wuhan, China 2 d ago.

### History of present illness

The patient had a history of HBV infection for over 20 years. He was initially treated with adefovir dipivoxil and entecavir since then. Adefovir was discontinued 5 years ago.

### History of past illness

The patient had no history of high blood pressure, diabetes, heart disease, or tumor.

### Personal and family history

The patient was married at the age of 25, with two sons. His wife was in good health and his family relations were harmonious. His parents were alive and healthy, and his two younger sisters were healthy.

### Physical examination

Physical examination revealed no swelling of lymph nodes throughout the body, clear breath sounds in both lungs, and no rales.

### Laboratory examinations

The patient was positive for nucleic acid test for COVID-19. The initial laboratory results included: His blood lymphocyte count was  $1.61 \times 10^9/L$ , the percentage of CD4+ T cells was 32.82%, and alanine aminotransferase (ALT) and aspartate transaminase (AST) were 56 U/L and 30 U/L, respectively. After that, ALT was increased to 102 U/L, and AST was slightly increased to 48 U/L. HBV DNA was lower than the detection limit (30 IU/mL). Hepatitis B surface antigen was 1356 cutoff index (COI; < 1.000), hepatitis B surface antibody 2 iu/L (2-10 iu/L), hepatitis B e-antigen 0.34 COI (< 1.000), hepatitis B e-antibody 0.563COI (> 1.000), and hepatitis B c-antibody 0.416 COI

(> 1.000).

### **Imaging examinations**

On day 6, a chest computed tomography scan showed progressive pneumonia.

---

## **FINAL DIAGNOSIS**

---

COVID-19 and hepatitis B virus infection.

---

## **TREATMENT**

---

After admission, the patient was treated with recombinant interferon-alpha-2b and lopinavir/ritonavir. Following this, he was treated with methylprednisolone (40 mg once daily). His lymphocyte count continued its downtrend to  $0.89 \times 10^9/L$ , CD4+ T cells further declined to 27.14%, and liver enzymes ALT and AST showed no significant changes. HBV DNA was increased to  $1.11 \times 10^2 IU/mL$ , although it was actually negative before this admission (Figure 1). Hence, tenofovir fumarate was added for possible HBV reactivation.

---

## **OUTCOME AND FOLLOW-UP**

---

The patient started to be afebrile, and liver enzymes ALT and AST decreased to 42 U/L and 17 U/L, respectively. The nucleic acid test for COVID-19 became negative twice then. HBV DNA became lower than the detection limit (30 IU/mL). HBV drug resistance gene of the HBV P region was negative too. Then, the patient was discharged. Both liver enzymes and HBV DNA were within normal range after discharge from hospital.

---

## **DISCUSSION**

---


As we know, unstandardized administration of nucleos(t)ide analog, glucocorticoids, chemotherapy drugs, and new biological agents such as monoclonal antibodies and antiviral drugs of hepatitis B virus can cause HBV reactivation[1]. This patient had used adefovir dipivoxil and entecavir for antiviral therapy for a long time. His HBV DNA was negative before the development of COVID-19. He had elevated liver enzymes and increased HBV DNA during the treatment of COVID-19. Thus, according to American Association for the Study of Liver Diseases guideline about the definition of HBV reactivation, he met the criteria for HBV reactivation. Besides, the long term usage of antiviral drugs that may cause HBV resistance to NAs is also possible[3]. However, his HBV resistance gene was tested and negative for entecavir and adefovir dipivoxil. Noncompliance is another reason that causes HBV reactivation[3], but our patient was followed in the clinic regularly, and he did not discontinue or reduce dose without physician's advice. Therefore, it could be possible that HBV reactivation in this patient was caused by COVID-19 or related treatment. The mechanism of HBV reactivation is not yet fully understood. Once the immune homeostasis between the virus and the body is disturbed, HBV reactivation may occur[4]. Previous studies have shown that COVID-19 patients may have impaired immune function and lower lymphocyte count, especially CD4+ T lymphocytes[2]. And glucocorticoid usage may decrease cellular immune function sharply. As a novel infectious disease, the pathogenesis of COVID-19 is yet unclear. This is the first case report of COVID-19 complicated with HBV reactivation.

---

## **CONCLUSION**

---

For COVID-19 patients complicated with hepatitis B, HBV reactivation may happen, and glucocorticoids need to be used cautiously.



**Figure 1** Time-course of CD4+ T cells, lymphocyte count, alanine aminotransferase, aspartate transaminase, and hepatitis B virus DNA. A: CD4+ T cells, lymphocyte count, and hepatitis B virus (HBV) DNA; B: Alanine aminotransferase, aspartate transaminase, and HBV DNA. ALT: Alanine aminotransferase; AST: Aspartate transaminase; HBV: Hepatitis B virus.

## REFERENCES

- Perrillo RP**, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology* 2015; **148**: 221-244. e3 [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038]
- Winker B**. [Remarks on the so-called feeling of hysteria]. *Nervenarzt* 1988; **59**: 752-753 [PMID: 3216940 DOI: 10.1093/cid/ciaa248]
- Ganem D**, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004; **350**: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]
- Loomba R**, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. *Gastroenterology* 2017; **152**: 1297-1309 [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

